Newsletter
Eris Lifesciences is now taking full control of its injectable medicines unit, Swiss Parenterals.
Swiss Parenterals, incorporated in 1997, manufactures parenteral products and supplies to over 80 countries.
What’s going on: the company already owned 70% and has now bought the remaining 30% for ₹423.3 crore, making Swiss a fully owned part of Eris.
Eris will pay for the remaining stake entirely by giving shares instead of cash. It plans to issue about 23 lakh new shares to Naishadh Shah, a director at Swiss Parenterals, who is selling the stake.
The buyout will help Eris take full control of operations, cut costs, and combine Swiss Parenterals’ finances completely with its own.
What it really means: Eris is strengthening its injectable medicines business by fully taking over Swiss Parenterals.
With complete control, Eris can improve product quality, expand global reach, cut costs, and bring more advanced injectable treatments to market, potentially improving availability and reliability of essential medicines.
